Lupin's margin expansion failed to prevent an unusually sharp post-results fall
Revenue growth outpaced costs and operating margin reached 33.25%, but the stock fell 8.30% by the next session after the consolidated results.
Filed 07 May 2026, 20:58 IST · after market close · Lupin Ltd (LUPIN)
Key takeaways
- Lupin's consolidated revenue grew 31.89% year on year, while expenses rose 14.80%, lifting operating margin by 9.94 percentage points.
- Net profit rose 87.72% year on year to Rs 1,468.67 cr despite the tax rate increasing by 11.15 percentage points.
- The stock fell 8.30% by the next session, far below its 0.83% median absolute move after the past eight results.
Price around the results
Revenue growth accelerated operating profit
Lupin's consolidated revenue rose 31.89% year on year and 4.29% sequentially, while operating profit increased 88.13% and 9.89%, respectively. Expenses grew only 14.80% year on year and 1.70% sequentially, allowing operating margin to expand to 33.25%. The company said its India business grew 11.5% year on year.
Margin recovery came with higher financing and depreciation costs
Operating margin improved 1.69 percentage points sequentially as revenue growth exceeded expense growth, reversing the decline to 31.56% in Q3FY26. Year on year, the margin expanded 9.94 percentage points, even as interest expense rose 34.86% and depreciation increased 13.63%. Other income contributed only 0.49% of pre-tax profit, so earnings were not materially supported by non-operating income.
Net profit growth was tempered by a higher tax rate
Profit before tax grew 115.22% year on year and 26.67% sequentially, but the tax rate rose to 23.82% from 12.67% a year earlier and 22.44% in Q3FY26. That tax-rate increase limited the conversion of pre-tax growth into net profit, although net profit still rose 87.72% year on year and 24.41% sequentially. FY26 operating margin ended at 33.25%, up from 27.55% in Q1FY26 after a Q3 dip.
Management outlined a broader FY27 product pipeline
Management said Lupin plans to launch more than 20 products in India and file more than 15 ANDAs in the US in FY27. It also said the India respiratory franchise is expected to outperform IPM growth by 1.2-1.3 times, while the company plans to expand its Extra-Urban division and hospital-channel collaborations. The presentation said Lupin signed a semaglutide licence and supply agreement with Galenicum covering 23 countries.
The market reaction was unusually negative
The stock fell 3.28% on the first reaction day and 8.30% by the next session, with trading volume at 2.61 times the reference level. The five-session decline was 7.48% and underperformed the benchmark by 4.67%. This was much weaker than the typical post-results move: the stock rose after three of the past eight results, fell after five, and had a median absolute move of 0.83%.
Margin remained above the healthcare peer median
Lupin's 33.25% operating margin was 9.87 percentage points above the 23.38% median for the 48 healthcare peers that had reported the same quarter. This places the company above the reported sector median despite the sequential volatility in its own margin.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹7,475 cr | ₹7,168 cr | +4.29% | +31.89% |
| Other income | ₹9 cr | ₹-312 cr | — | -83.55% |
| Expenses | ₹4,989 cr | ₹4,906 cr | +1.70% | +14.80% |
| Operating profit | ₹2,486 cr | ₹2,262 cr | +9.89% | +88.13% |
| Operating margin (%) | 33.25% | 31.56% | — | — |
| Interest | ₹120 cr | ₹115 cr | +4.51% | +34.86% |
| Depreciation | ₹447 cr | ₹313 cr | +42.76% | +13.63% |
| Profit before tax | ₹1,928 cr | ₹1,522 cr | +26.67% | +115.22% |
| Tax | ₹459 cr | ₹342 cr | +34.49% | +304.84% |
| Net profit | ₹1,469 cr | ₹1,181 cr | +24.41% | +87.72% |
| EPS (₹) | ₹31.96 | ₹25.74 | +24.16% | +88.78% |
Operating margin of 33.25% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -3.28% | -2.66% |
| Next session | -8.30% | — |
| 5 sessions | -7.48% | -4.67% |
| 15 sessions | -8.02% | — |
| 30 sessions | -4.88% | — |
Volume on the results session was 2.61× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Lupin's India business grew 11.5% year on year.
Guidance & outlook
- Lupin plans to launch more than 20 products in India in FY27.
- Lupin expects its India respiratory franchise to outperform IPM growth by 1.2-1.3 times.
- Lupin plans to file more than 15 ANDAs in the US in FY27.
- Lupin targets 20 complex product launches in regulated markets by 2028.
Expansion
- Lupin plans to expand its Extra-Urban division, Uday.
- Lupin plans a strategic expansion in the hospital channel through collaborations with retailers and channel partners.
New products
- Lupin launched 15 products in FY26.
New initiatives
- Lupin signed a license and supply agreement with Galenicum for semaglutide in 23 countries.
What to watch
- Whether operating margin holds above 33.25% after the Q3FY26 dip to 31.56%.
- Whether expenses continue to grow more slowly than revenue, after 14.80% expense growth against 31.89% revenue growth year on year.
- Progress on management's stated plan to launch more than 20 products in India and file more than 15 ANDAs in the US in FY27.